Skip to main content
. 2014 Jan 30;2014:583090. doi: 10.1155/2014/583090

Figure 4.

Figure 4

Optimized conditions: (a) chromatographic profile of the plasma spiked with emtricitabine (2 μg/mL) in the presence of the I.S lamivudine 0.2 μg/mL at pH value of 3.2 and identical compositions of mobile phase (phosphate dihydrogen phosphate buffer : methanol (40 mM) (85 : 15 v/v)) at a flow rate of 1 mL/min. (b) In vitro release profiles of emtricitabine loaded PLGA (50 : 50) (M.W 14,500 da) nanoparticles with cetrimide as stabilizer in pH 7.4 phosphate buffer. Data points shown are mean ± standard deviation (n = 3). (c) Chromatogram of plasma sample collected from rats 2 h after administration of free emtricitabine. (d) Chromatogram of plasma sample collected from rats 16 h after receiving oral administration of emtricitabine NPs.